LT2773326T - Lipidų-nukleorūgščių dalelių sterilios gamybos būdas - Google Patents
Lipidų-nukleorūgščių dalelių sterilios gamybos būdasInfo
- Publication number
- LT2773326T LT2773326T LTEP12829180.4T LT12829180T LT2773326T LT 2773326 T LT2773326 T LT 2773326T LT 12829180 T LT12829180 T LT 12829180T LT 2773326 T LT2773326 T LT 2773326T
- Authority
- LT
- Lithuania
- Prior art keywords
- sterilely
- nucleic acid
- acid particles
- producing lipid
- lipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/04—Making microcapsules or microballoons by physical processes, e.g. drying, spraying
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161556124P | 2011-11-04 | 2011-11-04 | |
PCT/IB2012/002916 WO2013064911A2 (en) | 2011-11-04 | 2012-11-02 | Single use system for sterilely producing lipid-nucleic acid particles |
Publications (1)
Publication Number | Publication Date |
---|---|
LT2773326T true LT2773326T (lt) | 2019-04-25 |
Family
ID=47178988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP12829180.4T LT2773326T (lt) | 2011-11-04 | 2012-11-02 | Lipidų-nukleorūgščių dalelių sterilios gamybos būdas |
Country Status (21)
Country | Link |
---|---|
US (1) | US8956572B2 (lt) |
EP (4) | EP3673898A1 (lt) |
JP (3) | JP6133883B2 (lt) |
KR (2) | KR102056702B1 (lt) |
CN (2) | CN103906504B (lt) |
AU (2) | AU2012330819B2 (lt) |
CA (2) | CA2853685C (lt) |
CY (1) | CY1121495T1 (lt) |
DK (1) | DK2773326T3 (lt) |
ES (1) | ES2721325T3 (lt) |
HR (1) | HRP20190481T1 (lt) |
HU (1) | HUE043809T2 (lt) |
LT (1) | LT2773326T (lt) |
PL (1) | PL2773326T3 (lt) |
PT (1) | PT2773326T (lt) |
RS (1) | RS58562B1 (lt) |
RU (2) | RU2647476C2 (lt) |
SI (1) | SI2773326T1 (lt) |
TR (1) | TR201904389T4 (lt) |
TW (3) | TWI618548B (lt) |
WO (2) | WO2013093648A2 (lt) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
ES2737960T3 (es) | 2010-10-01 | 2020-01-17 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
US9320297B2 (en) | 2012-03-22 | 2016-04-26 | Lemniscate Innovations Llc | Spherification/reverse spherification automated and integrated system and method |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
BR112014030714B1 (pt) | 2012-06-08 | 2020-12-22 | Nitto Denko Corporation | composto de lipídeo ionizável, composição, veículo de fármaco e formulação farmacêutica |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
CA2899155A1 (en) | 2013-02-05 | 2014-08-14 | 1Globe Health Institute Llc | Biodegradable and clinically-compatible nanoparticles as drug delivery carriers |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2014152031A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Ribonucleic acid purification |
HRP20211563T1 (hr) | 2013-07-11 | 2022-01-07 | Modernatx, Inc. | Pripravci koji sadrže sintetske polinukleotide koji kodiraju proteine srodne crispr-u i sintetske sgrna, te postupci njihove uporabe |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015048020A2 (en) * | 2013-09-24 | 2015-04-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for the manufacture of lipid nanoparticles |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CN103599549A (zh) * | 2013-11-22 | 2014-02-26 | 大连民族学院 | 一种siRNA/抗癌药物联合转运复合载体及其制备方法和应用 |
BR112016024644A2 (pt) | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
CN114344275A (zh) * | 2014-07-02 | 2022-04-15 | 川斯勒佰尔公司 | 信使rna的包封 |
EP4223285A3 (en) * | 2014-07-16 | 2023-11-22 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
CA2955250A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
WO2016045732A1 (en) * | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
BR112017014090A2 (pt) * | 2014-12-29 | 2018-03-06 | Bonac Corporation | composição, e, métodos para produção de uma composição e estabilização de uma molécula de ácido nucleico. |
CA2977768A1 (en) * | 2015-02-24 | 2016-09-01 | The University Of British Columbia | Continuous flow microfluidic system |
EP3288671A4 (en) | 2015-04-28 | 2019-01-16 | The University Of British Columbia | DISPOSABLE MICROFLUIDIC CARTRIDGE |
DK3324932T3 (da) * | 2015-07-22 | 2021-04-06 | Nitto Denko Corp | Sammensætninger og fremgangsmåder for nanopartikel lyofile former |
WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
US9938572B1 (en) * | 2015-09-08 | 2018-04-10 | Raindance Technologies, Inc. | System and method for forming an emulsion |
PT3350157T (pt) | 2015-09-17 | 2022-03-18 | Modernatx Inc | Compostos e composições para administração intracelular de agentes terapêuticos |
EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
EP3964200A1 (en) | 2015-12-10 | 2022-03-09 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
AU2016377681B2 (en) | 2015-12-22 | 2021-05-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
HRP20220525T1 (hr) | 2015-12-23 | 2022-05-27 | Modernatx, Inc. | Postupci uporabe polinukleotida koji kodiraju ligand ox40 |
KR102361123B1 (ko) | 2016-01-06 | 2022-02-09 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 분기 혼합기들 및 그 사용 및 제조 방법 |
WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
US10689873B2 (en) | 2016-03-10 | 2020-06-23 | Lonza Ltd | Customizable facility |
CA3017165A1 (en) | 2016-03-10 | 2017-09-14 | Lonza Ltd | Customizable facility |
WO2017223135A1 (en) * | 2016-06-24 | 2017-12-28 | Modernatx, Inc. | Lipid nanoparticles |
WO2018006052A1 (en) | 2016-06-30 | 2018-01-04 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
KR102480770B1 (ko) * | 2016-08-02 | 2022-12-22 | 론자 리미티드 | 맞춤형 시설 |
CN110312799A (zh) | 2016-08-17 | 2019-10-08 | 博德研究所 | 新型crispr酶和*** |
US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
CN109922794B (zh) * | 2016-08-18 | 2022-11-04 | 特洛伊.布雷莫 | 使用脂质体构建体将尿素递送至黄斑和视网膜的细胞 |
EP3315125A1 (en) * | 2016-10-31 | 2018-05-02 | Silence Therapeutics (London) Ltd | Lipid nanoparticle formulation |
WO2018089540A1 (en) * | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
PL3596041T3 (pl) | 2017-03-15 | 2023-03-06 | Modernatx, Inc. | Związek i kompozycje do dokomórkowego dostarczania środków terapeutycznych |
ES2911186T3 (es) | 2017-03-15 | 2022-05-18 | Modernatx Inc | Formas cristalinas de aminolípidos |
US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
WO2018191750A2 (en) | 2017-04-14 | 2018-10-18 | The Broad Institute Inc. | Novel delivery of large payloads |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
AU2017423053A1 (en) * | 2017-07-10 | 2020-01-23 | Immunovaccine Technologies Inc. | Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof |
EP3662913A4 (en) | 2017-08-04 | 2021-06-30 | Kyowa Kirin Co., Ltd. | LIPID NANOPARTICLES CONTAINING NUCLEIC ACID |
JP2019043216A (ja) | 2017-08-30 | 2019-03-22 | いすゞ自動車株式会社 | ステアリング装置 |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
SG11202002579SA (en) * | 2017-10-20 | 2020-05-28 | Biontech Rna Pharmaceuticals Gmbh | Preparation and storage of liposomal rna formulations suitable for therapy |
WO2019088193A1 (ja) * | 2017-11-01 | 2019-05-09 | 国立大学法人大阪大学 | 所望の粒径を有する脂質粒子を製造するための方法および装置の開発 |
CN111565706A (zh) * | 2017-11-09 | 2020-08-21 | 免疫疫苗技术公司 | 药物组合物、包括脂质囊泡颗粒尺寸设定的制备方法及其用途 |
EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH |
US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
WO2019204451A1 (en) * | 2018-04-17 | 2019-10-24 | Carnegie Mellon University | Enhanced lipid nanoparticle drug delivery using a negatively charged polymer |
CA3108920A1 (en) * | 2018-08-29 | 2020-03-05 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
CA3113353A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
EP3852732A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Peg lipids and uses thereof |
CA3113651A1 (en) * | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
US20220273567A1 (en) * | 2018-09-21 | 2022-09-01 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
EP3864163B1 (en) | 2018-10-09 | 2024-03-20 | The University of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto |
AU2019362031A1 (en) * | 2018-10-19 | 2021-04-08 | Translate Bio, Inc. | Pumpless encapsulation of messenger RNA |
BR112021014845A2 (pt) * | 2019-01-31 | 2021-11-03 | Modernatx Inc | Métodos de preparação de nanopartículas lipídicas |
WO2020191102A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
KR20220018960A (ko) * | 2019-03-19 | 2022-02-15 | 아크투루스 쎄라퓨틱스, 인크. | 지질-캡슐화된 rna 나노입자 제조 방법 |
CA3137789A1 (en) | 2019-05-07 | 2020-11-12 | Universidade Do Minho | Method for production of liposomes |
US20220220469A1 (en) | 2019-05-20 | 2022-07-14 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
CA3150458A1 (en) | 2019-08-14 | 2021-02-18 | Acuitas Therapeutics, Inc. | Improved lipid nanoparticles for delivery of nucleic acids |
CN114929205A (zh) | 2019-09-06 | 2022-08-19 | 世代生物公司 | 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法 |
JP7271374B2 (ja) * | 2019-09-10 | 2023-05-11 | 株式会社東芝 | 分析方法、分析基体、分析キット及び分析装置。 |
AR120080A1 (es) | 2019-09-19 | 2022-02-02 | Modernatx Inc | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos |
WO2021102411A1 (en) | 2019-11-22 | 2021-05-27 | Generation Bio Co. | Ionizable lipids and nanoparticle compositions thereof |
KR102409145B1 (ko) * | 2020-03-23 | 2022-06-15 | 프레스티지바이오로직스 주식회사 | 항체 의약품 제조 공정을 위한 버퍼 조제 및 이송 시스템 |
CN111467321A (zh) * | 2020-03-26 | 2020-07-31 | 深圳市新合生物医疗科技有限公司 | 一种mRNA核酸类药物胞内递送***、制备方法和应用 |
US11938227B2 (en) | 2020-09-13 | 2024-03-26 | Arcturus Therapeutics, Inc. | Lipid nanoparticles encapsulation of large RNA |
CN112843019A (zh) * | 2021-01-27 | 2021-05-28 | 江苏普瑞康生物医药科技有限公司 | 一种核酸脂质纳米粒组合物,包含其的药物制剂,及其制备方法和应用 |
EP4294450A1 (en) * | 2021-02-16 | 2023-12-27 | The Johns Hopkins University | Methods for preparation of plasmid dna/lipid particles with defined size for in vitro and in vivo transfection |
WO2022175366A1 (en) | 2021-02-17 | 2022-08-25 | Secoya Technologies | Method for producing lipid nanoparticles and lipid nanoparticles resulting therefrom |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
WO2022225368A1 (ko) * | 2021-04-22 | 2022-10-27 | (주)인벤티지랩 | 지질 나노입자의 제조 방법 및 이의 제조 장치 |
CN117642380A (zh) | 2021-06-14 | 2024-03-01 | 世代生物公司 | 阳离子脂质及其组合物 |
WO2023057596A1 (en) * | 2021-10-06 | 2023-04-13 | Leon-Nanodrugs Gmbh | Method for preparing lipid nanoparticles |
CA3236235A1 (en) | 2021-11-08 | 2023-05-11 | Orna Therapeutics, Inc. | Lipid nanoparticle compositions for delivering circular polynucleotides |
CN116549626A (zh) * | 2022-01-27 | 2023-08-08 | 深圳瑞吉生物科技有限公司 | 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用 |
WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
KR102475540B1 (ko) * | 2022-04-26 | 2022-12-08 | 주식회사 무진메디 | 약물이 담지된 지질 나노입자 제조 방법 및 제조 장치 |
WO2023239756A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4781871A (en) * | 1986-09-18 | 1988-11-01 | Liposome Technology, Inc. | High-concentration liposome processing method |
AU598601B2 (en) * | 1986-09-18 | 1990-06-28 | Liposome Technology, Inc. | High-concentration liposome processing method |
US4895452A (en) | 1988-03-03 | 1990-01-23 | Micro-Pak, Inc. | Method and apparatus for producing lipid vesicles |
JPH08512056A (ja) * | 1993-06-30 | 1996-12-17 | ジェネンテク・インコーポレイテッド | リポソームの製造法 |
IL122290A0 (en) | 1995-06-07 | 1998-04-05 | Inex Pharmaceuticals Corp | Lipid-nucleic acid complex its preparation and use |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US6395302B1 (en) | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
DE69841002D1 (de) * | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
US6855296B1 (en) | 1998-11-13 | 2005-02-15 | Optime Therapeutics, Inc. | Method and apparatus for liposome production |
AU756196B2 (en) | 1998-11-13 | 2003-01-09 | Optime Therapeutics, Inc. | Method and apparatus for liposome production |
US7094423B1 (en) | 1999-07-15 | 2006-08-22 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
WO2001005374A1 (en) | 1999-07-15 | 2001-01-25 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
EP1203614A1 (de) | 2000-11-03 | 2002-05-08 | Polymun Scientific Immunbiologische Forschung GmbH | Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln |
EP1306127B2 (en) * | 2001-10-26 | 2011-09-07 | OctoPlus PolyActive Sciences B.V. | Method for the preparation of purified microparticles |
US7223887B2 (en) | 2001-12-18 | 2007-05-29 | The University Of British Columbia | Multivalent cationic lipids and methods of using same in the production of lipid particles |
AU2003205048B2 (en) | 2002-01-09 | 2009-02-26 | Transave, Inc. | Efficient liposomal encapsulation |
US6712963B2 (en) | 2002-06-14 | 2004-03-30 | Scilog, Llc | Single-use manifold for automated, aseptic transfer of solutions in bioprocessing applications |
ATE485031T1 (de) | 2002-06-28 | 2010-11-15 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
FR2856940B1 (fr) * | 2003-07-04 | 2007-02-09 | Stedim Sa | Systeme clos a usage unique de melange, de stockage et d'homogeneisation de liquides en conditions propres ou steriles |
WO2005090403A2 (en) * | 2004-03-12 | 2005-09-29 | Biovest International, Inc. | Method and apparatus for antibody purification |
DK1773976T4 (da) | 2004-06-04 | 2020-02-10 | Global Life Sciences Solutions Usa Llc | Engangsbioreaktorsystemer og -fremgangsmåder |
US7410587B2 (en) | 2004-08-03 | 2008-08-12 | Scilog, Inc. | Liquid handling for filtration and preparative chromatography |
US7404969B2 (en) * | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
AU2006274413B2 (en) | 2005-07-27 | 2013-01-10 | Arbutus Biopharma Corporation | Systems and methods for manufacturing liposomes |
US8101741B2 (en) * | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US20090252836A1 (en) | 2006-04-11 | 2009-10-08 | Wingturf Co., Ltd. | Method of Gas Treatment |
EP1920765A1 (en) | 2006-11-07 | 2008-05-14 | Medigene AG | Liposome preparation by single-pass process |
WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
JP5322476B2 (ja) | 2008-03-31 | 2013-10-23 | テルモ株式会社 | リポソームの製造装置およびリポソームの製造方法 |
US8231787B2 (en) | 2008-05-06 | 2012-07-31 | Spf Innovations, Llc | Tangential flow filtration system |
EP2326331A4 (en) * | 2008-08-18 | 2013-05-15 | Merck Sharp & Dohme | NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION |
CA2739046A1 (en) | 2008-10-16 | 2010-04-22 | Marina Biotech, Inc. | Process and compositions for liposomal and effective delivery of nucleic acids |
CA2742776A1 (en) * | 2008-11-17 | 2010-05-20 | Enzon Pharmaceuticals, Inc. | Releasable cationic lipids for nucleic acids delivery systems |
WO2010080724A1 (en) * | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
CN102292077B (zh) * | 2009-01-20 | 2014-03-26 | 迈德涂料公司 | 一种涂料组合物及其用途 |
FR2943560B1 (fr) * | 2009-03-24 | 2011-05-27 | Jean Pascal Zambaux | Bioreacteur jetable et systeme d'agitation a usage unique |
WO2011140627A1 (en) * | 2009-11-04 | 2011-11-17 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
PT2506857T (pt) * | 2009-12-01 | 2018-05-14 | Translate Bio Inc | Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas |
US9670487B2 (en) * | 2010-01-22 | 2017-06-06 | Sirna Therapeutics, Inc. | Cationic lipids for oligonucleotide delivery |
WO2011127255A1 (en) | 2010-04-08 | 2011-10-13 | Merck Sharp & Dohme Corp. | Preparation of lipid nanoparticles |
PT2998289T (pt) * | 2011-06-08 | 2019-09-19 | Nitto Denko Corp | Compostos para direcionar a distribuição de fármaco e melhorar a atividade de sirna |
-
2012
- 2012-11-02 JP JP2014540573A patent/JP6133883B2/ja active Active
- 2012-11-02 KR KR1020147014826A patent/KR102056702B1/ko active IP Right Grant
- 2012-11-02 CN CN201280054027.8A patent/CN103906504B/zh active Active
- 2012-11-02 EP EP19205352.8A patent/EP3673898A1/en not_active Ceased
- 2012-11-02 CA CA2853685A patent/CA2853685C/en active Active
- 2012-11-02 HU HUE12829180A patent/HUE043809T2/hu unknown
- 2012-11-02 WO PCT/IB2012/003109 patent/WO2013093648A2/en active Application Filing
- 2012-11-02 TR TR2019/04389T patent/TR201904389T4/tr unknown
- 2012-11-02 DK DK12829180.4T patent/DK2773326T3/en active
- 2012-11-02 AU AU2012330819A patent/AU2012330819B2/en active Active
- 2012-11-02 WO PCT/IB2012/002916 patent/WO2013064911A2/en active Application Filing
- 2012-11-02 CA CA2853689A patent/CA2853689C/en active Active
- 2012-11-02 EP EP18209774.1A patent/EP3485875A1/en active Pending
- 2012-11-02 RU RU2014122432A patent/RU2647476C2/ru active
- 2012-11-02 JP JP2014540571A patent/JP6149041B2/ja active Active
- 2012-11-02 LT LTEP12829180.4T patent/LT2773326T/lt unknown
- 2012-11-02 PL PL12829180T patent/PL2773326T3/pl unknown
- 2012-11-02 ES ES12829180T patent/ES2721325T3/es active Active
- 2012-11-02 EP EP12829180.4A patent/EP2773326B1/en active Active
- 2012-11-02 CN CN201280054023.XA patent/CN103906503B/zh active Active
- 2012-11-02 KR KR1020147014822A patent/KR102046968B1/ko active IP Right Grant
- 2012-11-02 EP EP12848760.0A patent/EP2773328A2/en not_active Withdrawn
- 2012-11-02 PT PT12829180T patent/PT2773326T/pt unknown
- 2012-11-02 AU AU2012356239A patent/AU2012356239B2/en active Active
- 2012-11-02 RU RU2014122433A patent/RU2642640C2/ru active
- 2012-11-02 SI SI201231557T patent/SI2773326T1/sl unknown
- 2012-11-02 RS RS20190426A patent/RS58562B1/sr unknown
- 2012-11-05 TW TW101141082A patent/TWI618548B/zh active
- 2012-11-05 TW TW106116691A patent/TWI626952B/zh active
- 2012-11-05 TW TW101141084A patent/TWI615156B/zh active
- 2012-11-05 US US13/669,217 patent/US8956572B2/en active Active
-
2017
- 2017-04-20 JP JP2017083327A patent/JP6442551B2/ja active Active
-
2019
- 2019-03-11 HR HRP20190481TT patent/HRP20190481T1/hr unknown
- 2019-03-28 CY CY20191100358T patent/CY1121495T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190481T1 (hr) | Postupak za sterilnu pripravu nanočestica lipid-nukleinska kiselina | |
IL263389B (en) | A method for the production of modified 5-fluoro-1h-pyrazolopyridines | |
ZA201401133B (en) | Method for producing ternesite | |
EP2937329A4 (en) | PROCESS FOR PRODUCING ACETIC ACID | |
IL231549A0 (en) | A method for preparing glufosinate | |
PL2675539T3 (pl) | Sposób wytwarzania poli(kwasu hydroksykarboksylowego) | |
SG2014005623A (en) | Method for producing alpha-hydroxycarboxylic acid esters | |
ZA201304938B (en) | Process for producing nitrile-fatty acid compounds | |
PL2714589T3 (pl) | Dwuwodzianowo-półwodzianowy sposób wytwarzania kwasu fosforowego | |
EP2784063A4 (en) | PROCESS FOR THE PREPARATION OF BETA-MERCAPTOCARBONIC ACID | |
EP2735615A4 (en) | PROCESS FOR PRODUCING ORGANIC ACID | |
EP2687515A4 (en) | PROCESS FOR PREPARING A PYRAZOL CARBOXYLIC ACID DERIVATIVE | |
IL231877A0 (en) | A method for the production of dithiene tetracarboximides | |
EP2857510A4 (en) | PROCESS FOR PREPARING 3-ACETYLAMINO-4-HYDROXYBENZOIC ACID | |
EP2796562A4 (en) | METHOD FOR PRODUCING AN OPTICALLY ACTIVE SUBSTITUTED AMINO ACID | |
SG11201401916PA (en) | Method for producing formic acid | |
EP2757089A4 (en) | PROCESS FOR PRODUCING AMINO ACID | |
IL231878A0 (en) | A method for the production of dithiene tetracarboximides | |
EP2784064A4 (en) | PROCESS FOR PRODUCTION OF BETA-MERCAPTOCARBOXYLIC ACID |